226 related articles for article (PubMed ID: 28210154)
1. Epiregulin as a therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K
Lung Cancer (Auckl); 2015; 6():91-98. PubMed ID: 28210154
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
3. Role of Epiregulin in Lung Tumorigenesis and Therapeutic Resistance.
Sunaga N; Miura Y; Masuda T; Sakurai R
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398101
[TBL] [Abstract][Full Text] [Related]
4. The Role of EREG/EGFR Pathway in Tumor Progression.
Cheng WL; Feng PH; Lee KY; Chen KY; Sun WL; Van Hiep N; Luo CS; Wu SM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884633
[TBL] [Abstract][Full Text] [Related]
5. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
6. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling.
Iijima M; Anai M; Kodama T; Shibasaki Y
Biochem Biophys Res Commun; 2017 Jul; 489(1):83-88. PubMed ID: 28274874
[TBL] [Abstract][Full Text] [Related]
7. Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling.
Zhang Y; Qiu F; Ye T; Lee SH; Xu J; Jia L; Zeng R; Wang X; Hu X; Yan X; Li H; Lu Y; Wang X; Jiang R; Xu W
Stem Cell Res Ther; 2022 May; 13(1):197. PubMed ID: 35551652
[TBL] [Abstract][Full Text] [Related]
8. ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.
Nakamura T; Nishikawa Y; Shiokawa M; Takeda H; Yokode M; Matsumoto S; Muramoto Y; Ota S; Yoshida H; Okada H; Kuwada T; Marui S; Matsumori T; Maruno T; Uza N; Kodama Y; Hatano E; Seno H
J Pathol; 2023 Sep; 261(1):28-42. PubMed ID: 37345534
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells.
Zhang J; Iwanaga K; Choi KC; Wislez M; Raso MG; Wei W; Wistuba II; Kurie JM
Cancer Prev Res (Phila); 2008 Aug; 1(3):201-7. PubMed ID: 19138957
[TBL] [Abstract][Full Text] [Related]
10. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
12. Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.
Xu X; Chen W; Leng S; Padilla MT; Saxton B; Hutt J; Tessema M; Kato K; Kim KC; Belinsky SA; Lin Y
Carcinogenesis; 2017 Jun; 38(6):604-614. PubMed ID: 28472347
[TBL] [Abstract][Full Text] [Related]
13. Epiregulin (EREG) is upregulated through an IL-1β autocrine loop in Caco-2 epithelial cells with reduced CFTR function.
Massip-Copiz M; Clauzure M; Valdivieso ÁG; Santa-Coloma TA
J Cell Biochem; 2018 Mar; 119(3):2911-2922. PubMed ID: 29091309
[TBL] [Abstract][Full Text] [Related]
14. Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on
Job S; Reyniès A; Heller B; Weiss A; Guérin E; Macabre C; Ledrappier S; Bour C; Wasylyk C; Etienne-Selloum N; Brino L; Gaiddon C; Wasylyk B; Jung AC
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181806
[TBL] [Abstract][Full Text] [Related]
15. Epiregulin promotes hair growth via EGFR-medicated epidermal and ErbB4-mediated dermal stimulation.
Choi N; Kim WS; Oh SH; Sung JH
Cell Prolif; 2020 Sep; 53(9):e12881. PubMed ID: 32700456
[TBL] [Abstract][Full Text] [Related]
16. FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells.
Lee MH; Yanagawa J; Tran L; Walser TC; Bisht B; Fung E; Park SJ; Zeng G; Krysan K; Wallace WD; Paul MK; Girard L; Gao B; Minna JD; Dubinett SM; Lee JM
Am J Transl Res; 2020; 12(2):409-427. PubMed ID: 32194893
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of cross talk between tissue factor/active coagulation factor VII and epidermal growth factor receptor signalings in colon cancer cells in culture].
Chen HK; Dai Y; Wu T; Wang X; Wan YL; Tang JQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):931-936. PubMed ID: 29263461
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter.
Qu X; Sandmann T; Frierson H; Fu L; Fuentes E; Walter K; Okrah K; Rumpel C; Moskaluk C; Lu S; Wang Y; Bourgon R; Penuel E; Pirzkall A; Amler L; Lackner MR; Tabernero J; Hampton GM; Kabbarah O
Oncogene; 2016 Dec; 35(50):6403-6415. PubMed ID: 27270421
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
20. Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity.
Song NJ; Lee A; Yasmeen R; Shen Q; Yang K; Kumar SB; Muhanna D; Arnipalli S; Noria SF; Needleman BJ; Hazey JW; Mikami DJ; Ortega-Anaya J; Jiménez-Flores R; Prokop J; Ziouzenkova O
Cells; 2022 Jan; 11(3):. PubMed ID: 35159237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
